Head, Neck, Thyroid, and CNS Malignancies

Daniel R., 34, a middle-school science teacher and cross-country coach whose first seizure ever interrupted a faculty meeting eighteen months ago. The disagreement is whether starting a newer targeted drug now is worth delaying the definitive treatment that still carries the best long-term evidence, especially with family planning in the mix.

V.N., 68, a retired librarian whose forty years cataloguing a small-town collection made her own staff the first to notice something wrong. The disagreement is whether the one positive signal in the field's largest trial actually describes a patient her age at all.

Marisol K., 52, an accountant doing well on her most recent HER2-directed therapy when small, asymptomatic brain metastases turned up on a routine scan. The disagreement is whether a new brain lesion means the systemic regimen has actually failed, or just that it was never going to reach there in the first place.

Walter B., a construction supervisor for close to forty years, left with bilateral hearing loss from decades on job sites before hearing protection was standard. The disagreement is which of cisplatin's two real toxicities his own health history makes the more urgent one to protect against.

Denise A., who ran a hair salon for thirty years before selling it just over a year ago, now recurring with symptomatic liver metastases eight months after chemoradiation. The disagreement is whether her biomarker score or the actual pace of her disease should decide how much therapy she starts with.

Claire T., a marathon runner who has never smoked and has read everything she can find since her diagnosis, asking directly for less treatment. The disagreement is what real de-escalation options actually exist for her outside a clinical trial, once a tempting-sounding substitution is checked against the trial that already tested it.

Harold F., a mail carrier for thirty-four years who still walks two miles most mornings out of habit, now progressing on radioactive-iodine-refractory thyroid cancer with blood pressure that won't stay controlled on three drugs. The disagreement is whether the trial behind his best option actually describes a patient with his cardiovascular profile.

Sandra V., a third-grade teacher who found a firm lump in her own neck while adjusting a scarf mid-field-trip planning. The disagreement is whether waiting for access to a superior targeted drug is safer than starting a broader multikinase inhibitor now, given how fast her disease is actually moving.

N.F., whose small, painless neck lump grew enough in ten days that her visiting daughter insisted on an immediate doctor's visit. The disagreement is whether a fast-acting targeted therapy can really be trusted to outrun an airway emergency, once the evidence behind "fast" is read closely for what it actually measured.

Amir T., who moved to the country in his twenties to open a restaurant with his brother and blamed his ear fullness on standing too close to the kitchen exhaust fans. The disagreement is what an unexpectedly low viral-DNA signal is actually allowed to change about a treatment plan built on his cancer's stage.